Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innate Pharma S.A. ADR
(NQ:
IPHA
)
2.070
+0.090 (+4.55%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innate Pharma S.A. ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
June 16, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
June 12, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
June 10, 2023
From
Innate Pharma SA
Via
Business Wire
Why Shares of Innate Pharma Jumped Thursday
June 08, 2023
The company's collaboration agreement with Sanofi could soon pay off.
Via
The Motley Fool
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
June 08, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
June 07, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
May 26, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
May 23, 2023
From
Innate Pharma SA
Via
Business Wire
Outcome of Innate Pharma’s 2023 Annual General Meeting
May 12, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
May 10, 2023
From
Innate Pharma SA
Via
Business Wire
Number of shares and voting rights of Innate Pharma as of May 1, 2023
May 09, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
May 03, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
May 03, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
April 26, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
April 21, 2023
From
Innate Pharma SA
Via
Business Wire
Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis
April 19, 2023
Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...
Via
Benzinga
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023
April 18, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023
April 07, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F
April 06, 2023
From
Innate Pharma SA
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 03, 2023
Via
Benzinga
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
April 03, 2023
From
Innate Pharma SA
Via
Business Wire
Earnings Scheduled For March 23, 2023
March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Via
Benzinga
Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update
March 23, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023
March 20, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results
March 16, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Provides Update on Silicon Valley Bank Exposure
March 13, 2023
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2023
February 21, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
February 07, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers
January 25, 2023
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
January 16, 2023
From
Innate Pharma SA
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.